Plasma Endoglin is Associated with Favorable Outcome for Pemetrexed-Based Therapy in Advanced Non-Small Cell Lung Cancer

doi:10.2147/CMAR.S338957

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24016

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24016

Title:	Plasma Endoglin is Associated with Favorable Outcome for Pemetrexed-Based Therapy in Advanced Non-Small Cell Lung Cancer
Authors:	Li, CH;Ko, JL;Hsiao, YP;Tsai, MH;Lai, YC;Hsin, IL;Kang, YT;Sheu, GT;Lin, WL;Wu, MF
Keywords:	endoglin;pemetrexed-based therapy;prognostic factor;non-squamous non-small cell lung cancer;biomarker
Date:	2021
Issue Date:	2022-08-05T09:46:29Z (UTC)
Publisher:	DOVE MEDICAL PRESS LTD
ISSN:	1179-1322
Abstract:	Purpose: Pemetrexed-based chemotherapy (Pem-C) is the first-line chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC). However, limited tumor-associated proteins in blood are available to predict pemetrexed response and/or survival. Patients and Methods: Plasma samples from three responders and three nonresponders with stage IIIB-IV NSCLC were collected prior to Pem-C and analyzed using Proteome Profiler (TM) Human XL Oncology Array to detect 84 oncology-related proteins. The plasma concentrations of cathepsin S, endoglin (ENG), and matrix metalloproteinases 3 and 9 in 71 patients with advanced NSCLC treated with Pem-C were further measured using enzyme-linked immunosorbent assay based on the remarkable differences in the four proteins between responders and nonresponders in the array results. Results: Pem-C responders had significantly higher ENG levels but not the other three markers than nonresponders (mean ENG level: 27.1 +/- 7.4 vs 22.3 +/- 6.9, p < 0.01). High ENG concentration was correlated with improved progression-free survival (hazard ratio [HR]: 0.52, 95% confidence interval [CI]: 0.31-0.86, p < 0.01) and overall survival (HR: 0.55, 95% CI: 0.32-0.94,p < 0.05) in patients treated with Pem-C, and the ENG level was an independent factor in our cohort (HR: 0.54, 95% CI: 0.33-0.89, p < 0.05). ENG concentration in Pem-C responders also significantly increased at the time of best response (p < 0.05). Conclusion: Cumulatively, this study reveals that ENG is correlated with Pem-C responsiveness in patients, which indicates the potential use of plasma ENG levels as a noninvasive biomarker for pemetrexed-based treatment in patients with non-squamous NSCLC.
URI:	http://dx.doi.org/10.2147/CMAR.S338957 https://www.webofscience.com/wos/woscc/full-record/WOS:000735382200002 https://ir.csmu.edu.tw:8080/handle/310902500/24016
Relation:	CANCER MANAGEMENT AND RESEARCH ,2021,v13 , P9305-9318
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	175	View/Open

Loading...